Effect of Selumetinib versus Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

IMPORTANCE: Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in MAPK pathway activation. OBJECTIVE: To assess the efficacy of selumetinib, a selective, non-ATP competitive inhibitor of MEK1 and MEK2, in uveal melanoma. DESIGN: Randomized open-label phase II clinical trial co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA
Main Authors: Carvajal, Richard D., Sosman, Jeffrey A., Quevedo, Jorge Fernando, Milhem, Mohammed M., Joshua, Anthony Michael, Kudchadkar, Ragini R., Linette, Gerald P., Gajewski, Thomas F., Lutzky, Jose, Lawson, David H., Lao, Christopher D., Flynn, Patrick J., Albertini, Mark R., Sato, Takami, Lewis, Karl, Doyle, Austin, Ancell, Kristin, Panageas, Katherine S., Bluth, Mark, Hedvat, Cyrus, Erinjeri, Joseph, Ambrosini, Grazia, Marr, Brian, Abramson, David, Dickson, Mark Andrew, Wolchok, Jedd D., Chapman, Paul B., Schwartz, Gary K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249701/
https://ncbi.nlm.nih.gov/pubmed/24938562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2014.6096
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados